All News Stories
Analysts Just Made A Captivating Upgrade To Their T2 Biosystems, Inc. (NASDAQ:TTOO) Forecasts
by admin •
T2 Biosystems, Inc. (NASDAQ:TTOO) shareholders will have a reason to smile today, with the analysts making substantial…
Analysts Just Shipped A Dazzling Upgrade To Their Dynavax Technologies Corporation (NASDAQ:DVAX) Estimates
by admin •
Celebrations may be in order for Dynavax Technologies Corporation (NASDAQ:DVAX) shareholders, with the analysts…
Norwegian Air suffers body blow as govt rules out more support
by admin •
The Norwegian government will not provide additional financial support for pandemic-hit Norwegian Air , it said on Monday, leaving the cash-strapped carrier in a precarious situation. “That the government has decided to reject the request for funds is disappointing and feels like a punch in the gut for everyone at Norwegian,” Chief Executive Jacob Schram…
Rolls-Royce signs MoU with CEZ for compact nuclear power stations
by admin •
Stock market news live updates: Stock futures open higher after Biden victory
by admin •
Stock futures opened higher Sunday evening as traders took in President-elect Joe Biden’s victory in the U.S. presidential election, ending a days-long nail-biter over which candidate would prevail in winning the White House.
Rolls-Royce signs MoU with Exelon for compact nuclear power stations
by admin •
Cramer Gives His Opinion On Workhorse, Alibaba And More
by admin •
On CNBC's "Mad Money Lightning Round," Jim Cramer said he would pick First Solar Inc. (NASDAQ: FSLR) over Solaredge Technologies Inc. (NASDAQ: SEDG).Plantronics Inc. (NYSE: PLT) is a good company and a very high quality stock, he said. He prefers lower-end companies, more gaming oriented, but he doesn't want to go against the call and…
How a Biden presidency could change your tax bill
by admin •
A victory by Democratic presidential candidate Joe Biden in the November election could significantly change tax bills for a slew of Americans. Here's what you need to know.
Biogen Alzheimer’s Drug Fails to Gain FDA Panel’s Backing
by admin •
(Bloomberg) — Biogen Inc.’s experimental Alzheimer’s disease therapy failed to gain support from a panel of U.S. Food and Drug Administration advisers on Friday, putting the drug at a crossroads as the agency weighs approval.The outside experts voted 8 to 1, with 2 undecided, that data from a single clinical trial with positive results was…